A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Healthy Study Participants

Interventions

DRUG

bimekizumab

Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.

Trial Locations (2)

UP0119 2, Glendale

UP0119 1, Berlin

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY